WHO ICTRP trial
Losartan Combined with Lenvatinib for Postoperative Adjuvant Therapy in Patients…
ChiCTR2500114812 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2500114812 |
|---|---|
| Public title | Losartan Combined with Lenvatinib for Postoperative Adjuvant Therapy in Patients with Tumor Budding-Positive Hepatocellular Carcinoma: A Multicenter, Prospective, Single-Arm Trial. |
| Scientific title | Losartan Combined with Lenvatinib for Postoperative Adjuvant Therapy in Patients with Tumor Budding-Positive Hepatocellular Carcinoma: A Multicenter, Prospective, Single-Arm Trial. |
| Primary sponsor | Xi'an Jiaotong University Second Affiliated Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Countries | China |
| Conditions | tumor budding positive hepatocellular carcinoma |
| Interventions | Lenvatinib+losartan treatment group:Targeted+collagen degradation therapy |
| Registration date | Dec 17, 2025 |
| Target size | Lenvatinib+losartan treatment group:56 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: